Cargando…

Production and separation of (43)Sc for radiopharmaceutical purposes

BACKGROUND: The favorable decay properties of (43)Sc and (44)Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage (43)Sc (T(1/2) = 3.89 h, Eβ(+) (av) = 476 keV [88%]) exhibits over (44)Sc, however, is the absence of co-emitted high energy γ-rays. While...

Descripción completa

Detalles Bibliográficos
Autores principales: Domnanich, Katharina A., Eichler, Robert, Müller, Cristina, Jordi, Sara, Yakusheva, Vera, Braccini, Saverio, Behe, Martin, Schibli, Roger, Türler, Andreas, van der Meulen, Nicholas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824704/
https://www.ncbi.nlm.nih.gov/pubmed/29503855
http://dx.doi.org/10.1186/s41181-017-0033-9
_version_ 1783302071237214208
author Domnanich, Katharina A.
Eichler, Robert
Müller, Cristina
Jordi, Sara
Yakusheva, Vera
Braccini, Saverio
Behe, Martin
Schibli, Roger
Türler, Andreas
van der Meulen, Nicholas P.
author_facet Domnanich, Katharina A.
Eichler, Robert
Müller, Cristina
Jordi, Sara
Yakusheva, Vera
Braccini, Saverio
Behe, Martin
Schibli, Roger
Türler, Andreas
van der Meulen, Nicholas P.
author_sort Domnanich, Katharina A.
collection PubMed
description BACKGROUND: The favorable decay properties of (43)Sc and (44)Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage (43)Sc (T(1/2) = 3.89 h, Eβ(+) (av) = 476 keV [88%]) exhibits over (44)Sc, however, is the absence of co-emitted high energy γ-rays. While the production and application of (44)Sc has been comprehensively discussed, research concerning (43)Sc is still in its infancy. This study aimed at developing two different production routes for (43)Sc, based on proton irradiation of enriched (46)Ti and (43)Ca target material. RESULTS: (43)Sc was produced via the (46)Ti(p,α)(43)Sc and (43)Ca(p,n)(43)Sc nuclear reactions, yielding activities of up to 225 MBq and 480 MBq, respectively. (43)Sc was chemically separated from enriched metallic (46)Ti (97.0%) and (43)CaCO(3) (57.9%) targets, using extraction chromatography. In both cases, ~90% of the final activity was eluted in a small volume of 700 μL, thereby, making it suitable for direct radiolabeling. The prepared products were of high radionuclidic purity, i.e. 98.2% (43)Sc were achieved from the irradiation of (46)Ti, whereas the product isolated from irradiated (43)Ca consisted of 66.2% (43)Sc and 33.3% (44)Sc. A PET phantom study performed with (43)Sc, via both nuclear reactions, revealed slightly improved resolution over (44)Sc. In order to assess the chemical purity of the separated (43)Sc, radiolabeling experiments were performed with DOTANOC, attaining specific activities of 5–8 MBq/nmol, respectively, with a radiochemical yield of >96%. CONCLUSIONS: It was determined that higher (43)Sc activities were accessible via the (43)Ca production route, with a comparatively less complex target preparation and separation procedure. The product isolated from irradiated (46)Ti, however, revealed purer (43)Sc with minor radionuclidic impurities. Based on the results obtained herein, the (43)Ca route features some advantages (such as higher yields and direct usage of the purchased target material) over the (46)Ti path when aiming at (43)Sc production on a routine basis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s41181-017-0033-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5824704
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-58247042018-02-28 Production and separation of (43)Sc for radiopharmaceutical purposes Domnanich, Katharina A. Eichler, Robert Müller, Cristina Jordi, Sara Yakusheva, Vera Braccini, Saverio Behe, Martin Schibli, Roger Türler, Andreas van der Meulen, Nicholas P. EJNMMI Radiopharm Chem Research Article BACKGROUND: The favorable decay properties of (43)Sc and (44)Sc for PET make them promising candidates for future applications in nuclear medicine. An advantage (43)Sc (T(1/2) = 3.89 h, Eβ(+) (av) = 476 keV [88%]) exhibits over (44)Sc, however, is the absence of co-emitted high energy γ-rays. While the production and application of (44)Sc has been comprehensively discussed, research concerning (43)Sc is still in its infancy. This study aimed at developing two different production routes for (43)Sc, based on proton irradiation of enriched (46)Ti and (43)Ca target material. RESULTS: (43)Sc was produced via the (46)Ti(p,α)(43)Sc and (43)Ca(p,n)(43)Sc nuclear reactions, yielding activities of up to 225 MBq and 480 MBq, respectively. (43)Sc was chemically separated from enriched metallic (46)Ti (97.0%) and (43)CaCO(3) (57.9%) targets, using extraction chromatography. In both cases, ~90% of the final activity was eluted in a small volume of 700 μL, thereby, making it suitable for direct radiolabeling. The prepared products were of high radionuclidic purity, i.e. 98.2% (43)Sc were achieved from the irradiation of (46)Ti, whereas the product isolated from irradiated (43)Ca consisted of 66.2% (43)Sc and 33.3% (44)Sc. A PET phantom study performed with (43)Sc, via both nuclear reactions, revealed slightly improved resolution over (44)Sc. In order to assess the chemical purity of the separated (43)Sc, radiolabeling experiments were performed with DOTANOC, attaining specific activities of 5–8 MBq/nmol, respectively, with a radiochemical yield of >96%. CONCLUSIONS: It was determined that higher (43)Sc activities were accessible via the (43)Ca production route, with a comparatively less complex target preparation and separation procedure. The product isolated from irradiated (46)Ti, however, revealed purer (43)Sc with minor radionuclidic impurities. Based on the results obtained herein, the (43)Ca route features some advantages (such as higher yields and direct usage of the purchased target material) over the (46)Ti path when aiming at (43)Sc production on a routine basis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s41181-017-0033-9) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-11-25 /pmc/articles/PMC5824704/ /pubmed/29503855 http://dx.doi.org/10.1186/s41181-017-0033-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Domnanich, Katharina A.
Eichler, Robert
Müller, Cristina
Jordi, Sara
Yakusheva, Vera
Braccini, Saverio
Behe, Martin
Schibli, Roger
Türler, Andreas
van der Meulen, Nicholas P.
Production and separation of (43)Sc for radiopharmaceutical purposes
title Production and separation of (43)Sc for radiopharmaceutical purposes
title_full Production and separation of (43)Sc for radiopharmaceutical purposes
title_fullStr Production and separation of (43)Sc for radiopharmaceutical purposes
title_full_unstemmed Production and separation of (43)Sc for radiopharmaceutical purposes
title_short Production and separation of (43)Sc for radiopharmaceutical purposes
title_sort production and separation of (43)sc for radiopharmaceutical purposes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824704/
https://www.ncbi.nlm.nih.gov/pubmed/29503855
http://dx.doi.org/10.1186/s41181-017-0033-9
work_keys_str_mv AT domnanichkatharinaa productionandseparationof43scforradiopharmaceuticalpurposes
AT eichlerrobert productionandseparationof43scforradiopharmaceuticalpurposes
AT mullercristina productionandseparationof43scforradiopharmaceuticalpurposes
AT jordisara productionandseparationof43scforradiopharmaceuticalpurposes
AT yakushevavera productionandseparationof43scforradiopharmaceuticalpurposes
AT braccinisaverio productionandseparationof43scforradiopharmaceuticalpurposes
AT behemartin productionandseparationof43scforradiopharmaceuticalpurposes
AT schibliroger productionandseparationof43scforradiopharmaceuticalpurposes
AT turlerandreas productionandseparationof43scforradiopharmaceuticalpurposes
AT vandermeulennicholasp productionandseparationof43scforradiopharmaceuticalpurposes